The company has not filed an annual or quarterly report since its FY2021 10-K, filed Feb 23, 2022. Its latest SEC filing is a 4 from Jan 29, 2024.
10-K for FY2021, filed Feb 23, 2022
The sections below describe the company as of the FY2021 annual report.
Develops investigational medicines for patients with gastrointestinal, skin and cardiovascular conditions.
10-K for FY2021, filed Feb 23, 2022
Other biopharmaceutical companies pay Arena for licenses to drug rights and related research and development services. Payments can include upfront fees, research funding and expense reimbursements as work is performed, milestone payments when development goals are reached, and royalties tied to licensed-product sales.
10-K for FY2021, filed Feb 23, 2022The Company’s revenues to date have been generated primarily through collaboration and license agreements. The Company’s collaboration and…View ↗
The Company generates revenue from licensing its intellectual property including know-how and development and commercialization rights.…View ↗
The Company generates revenue from research, development and regulatory services it provides to its customers in connection with the…View ↗
The Company’s contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone…View ↗
Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. The…View ↗
$54K
10-K for FY2021, filed Feb 24, 2022
$54K ↗
Other biopharmaceutical companies are typically the customers, licensing Arena's intellectual property or buying related research, development and other services under collaboration or license agreements.
10-K for FY2021, filed Feb 23, 2022The Company’s customers are typically other biopharmaceutical companies to which it licenses its intellectual property, or sells research…View ↗
10-K for FY2021, filed Feb 23, 2022
The Company’s customers are typically other biopharmaceutical companies to which it licenses its intellectual property, or sells research…View ↗
No. It lost $616.4M in FY2021.
10-K for FY2021, filed Feb 24, 2022
−$624.3MView ↗
10-K for FY2021, filed Feb 24, 2022
−$616.4MView ↗
10-K for FY2021, filed Feb 24, 2022
−$453MView ↗
8-K, filed Mar 11, 2022
As described in the Introductory Note, on March 11, 2022, the Merger was completed. Upon the consummation of the Merger, the Company became…View ↗
Shrank. Revenue fell 100% in 4 years, from $21.3M in FY2017 to $54K in FY2021, about 78% a year.
Olorinab strategy
The older report described olorinab in clinical evaluation for gastrointestinal pain; the latest describes Arena as considering strategic options for the program.
10-K for FY2018, filed Feb 28, 2019 10-K for FY2021, filed Feb 23, 2022Our most advanced investigational clinical programs are: etrasimod (APD334), which we are evaluating in late-stage clinical programs in…View ↗
Etrasimod, which we are evaluating in a Phase 3 program for ulcerative colitis, or UC, a Phase 2b/3 program for Crohn’s disease, or CD, a…View ↗
Competes with AbbVie, Takeda Pharmaceuticals, Janssen Biotech, Pfizer, Bristol Myers Squibb, Gilead Sciences, Galapagos, Eli Lilly, Regeneron, Sanofi, Leo Pharma, Lee’s Pharma, and AdvanceCor
10-K for FY2021, filed Feb 23, 2022Etrasimod is currently in development for the treatment of IBD, including in a Phase 3 program in UC and in a Phase 2b/3 program in CD. If…View ↗
Loading...
